The InVision-Plus CS is treated with Bacterin’s patented antimicrobial technology to offer the combined antibacterial protection of chlorhexidine and silver. The device is designed to reduce deadly, catheter-related bloodstream infections.
Bacterin will receive a royalty on all devices treated for RyMed.
RyMed president and CEO Dana Ryan said, “Our companies have put in a tremendous effort over several years to develop the InVision-Plus CS connector, combining RyMed’s InVision-Plus technology with Bacterin’s chlorhexidine/silver ion engineering.”
The proprietary needleless connector design is combined with Bacterin’s patent-pending antimicrobial septa treatment that is effective for the life of the connector against Acinetobacter baumannii, Methicillin-resistant Staphylococcus aureus, Staphylococcus aureus, Escherichia coli, Candida albicans, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus epidermidis.
Bacterin president and CEO Guy Cook said, “In 2001, as a result of a revision in the Bloodborne Pathogen Standard, the use of needleless systems was adopted by most healthcare facilities. Today, with FDA support and the reimbursement changes by Medicare and Medicaid, we anticipate a tremendous need for our products.”
Belgrade, Montana-based Bacterin’s medical device division develops anti-microbial coatings based upon proprietary coating technologies.
Bacterin’s strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination on medical devices drug delivery, local (as opposed to systemic) pain management, and anti-thrombotic factors for medical device applications.
RyMed Technologies specializes in the development and marketing of safety products in the field of intravenous catheter care management.
